Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease

Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02233062

Enrollment

Registered

2014-09-08

Start date

2013-05-31

Completion date

2014-08-31

Last updated

2014-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Keywords

Crohn's Disease, semen quality, enteral nutrition, CDAI score higher than 150

Brief summary

The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with crohn's disease.

Detailed description

The highest age- and sex-adjusted incidence rates for Crohn's Disease (CD) occur during the peak reproductive years. In addition, gastroenterologists frequently advise and manage patients with CD who desire to conceive. Enteral nutrition therapy is effective for induction and maintenance of remission in reproductive age men with CD. However, there is no available data on the effects of enteral nutrition therapy on semen quality. The purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with CD.

Interventions

DIETARY_SUPPLEMENTExclusive Enteral Nutrition Therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Crohn' Disease * Male patients * Age: 18-40 years old * Receive 3-months exclusive enteral nutrition therapy

Exclusion criteria

* Used any experimental therapy in the 8 weeks before study entry date * Had previously documented problems with male reproductive health, such as low sperm count, impotence, or malignancy * The use of concomitant medication including sulphasalazine, 5-aminosalicylic acid or other immune-suppressives. * Unable to complete the 3-months exclusive enteral nutrition therapy.

Design outcomes

Primary

Measure	Time frame	Description
Sperm motility	Up to 3 months	Sperm motility is a useful marker of sperm quality. The normal level of sperm motility (World Health Organization criteria) should be higher than 50%.

Secondary

Measure	Time frame
Crohn's Disease Activity Index	Up to 3 months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026